Mylan Asks Supreme Court To Review Notice Provision In Sandoz’s Patent Drug Suit

(April 28, 2016, 1:49 PM EDT) -- WASHINGTON, D.C. — Mylan Inc. in a March 21 an amicus curiae brief asks the U.S. Supreme Court to grant Sandoz Inc.’s petition to review whether an appellate court erred in finding that biosimilar makers must wait until their products receive U.S. Food and Drug Administration approval before providing 180-day advance notice of sales because the lower court’s decision will deny patients lower-priced biologic medications longer than Congress intended (Sandoz, Inc. v. Amgen, Inc. and Amgen Manufacturing, Ltd., No. 15-1039, U.S. Sup.).

(Amicus curiae brief available....
To view the full article, register now.